Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 41.15 CHF -0.48% Market Closed
Market Cap: 498.8m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Wall Street
Price Targets

BSLN Price Targets Summary
Basilea Pharmaceutica AG

Wall Street analysts forecast BSLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSLN is 88.27 CHF with a low forecast of 52.52 CHF and a high forecast of 126 CHF.

Lowest
Price Target
52.52 CHF
28% Upside
Average
Price Target
88.27 CHF
115% Upside
Highest
Price Target
126 CHF
206% Upside
Basilea Pharmaceutica AG Competitors:
Price Targets
PTCT
PTC Therapeutics Inc
32% Upside
7774
Japan Tissue Engineering Co Ltd
176% Upside
NTLA
Intellia Therapeutics Inc
401% Upside
MAAT
Maat Pharma SA
108% Upside
ALRN
Aileron Therapeutics Inc
511% Upside
EGTX
Egetis Therapeutics AB (publ)
101% Upside
SRZN
Surrozen Inc
175% Upside
OSTX
OS Therapies Inc
237% Upside

Revenue
Forecast

Revenue Estimate
Basilea Pharmaceutica AG

For the last 8 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 15%. The projected CAGR for the next 4 years is 10%.

15%
Past Growth
10%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 4 years is 43%.

N/A
Past Growth
43%
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Net Income
Forecast

Net Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 4 years is 62%.

N/A
Past Growth
62%
Estimated Growth
Estimates Accuracy
-24%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BSLN's stock price target?
Price Target
88.27 CHF

According to Wall Street analysts, the average 1-year price target for BSLN is 88.27 CHF with a low forecast of 52.52 CHF and a high forecast of 126 CHF.

What is Basilea Pharmaceutica AG's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 15%. The projected CAGR for the next 4 years is 10%.

What is Basilea Pharmaceutica AG's Operating Income forecast?
Projected CAGR
43%

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 4 years is 43%.

What is Basilea Pharmaceutica AG's Net Income forecast?
Projected CAGR
62%

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 4 years is 62%.

Back to Top